BioXcel Therapeutics (BTAI) Assets Average (2018 - 2026)

BioXcel Therapeutics' Assets Average history runs 9 years deep, the most recent figure standing at $39.5 million for Q1 2026.

• On a quarterly basis, Assets Average rose 2.65% year-over-year to $39.5 million in Q1 2026; TTM through Mar 2026 was $39.5 million, a 2.65% increase from a year earlier, with the FY2025 full-year figure at $41.6 million, down 25.69% from the prior year.
• Assets Average fell to $39.5 million in Q1 2026 per BTAI's latest filing, from $44.9 million in the prior quarter.
• Across five years, Assets Average topped out at $246.5 million in Q3 2022 and bottomed at $32.2 million in Q2 2025.
• The 5-year median for Assets Average is $78.0 million (2024), against an average of $113.5 million.
• Across the five-year window, Assets Average increased 7.18% in 2022 and tumbled 61.36% in 2023, its largest moves.
• Year by year, Assets Average stood at $225.3 million in 2022, then tumbled by 61.36% to $87.1 million in 2023, then sank by 49.91% to $43.6 million in 2024, then increased by 2.84% to $44.9 million in 2025, then slipped by 12.0% to $39.5 million in 2026.
• Per Business Quant, the three latest BTAI Assets Average figures stand at $39.5 million (Q1 2026), $44.9 million (Q4 2025), and $35.3 million (Q3 2025).